CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &a
http://www.businesswire.com/images/Powered-by-Business-Wire.gifGo to Source
https://feed.businesswire.com/rss/home/?rss=G1QFDERJXkJeEVlZWA==&_gl=1*1m4yt6c*_gcl_au*ODY2ODgwODguMTczNjM1MjA5OA..*_ga*MTQ4NTQ4MjYyMi4xNzM2MzUyMDk4*_ga_ZQWF70T3FK*MTczNjM1MjA5OC4xLjEuMTczNjM1MjIwOS42MC4wLjA.